Literature DB >> 19002792

Nucleotide excision repair and anti-cancer chemotherapy.

E Reed1.   

Abstract

DNA repair is an important effector of anti-cancer drug resistance. In recent years, it has become apparent that DNA repair is an extremely complex process. Processes within DNA repair that may contribute to one or more drug resistance phenotypes include; O-6-alkyltransferase activity, base excision repair, mismatch repair, nucleotide excision repair, and gene specific repair. Clearly, several of these processes may show increased activity within any single cell, or tumor, at any one time. This review attempts to touch briefly upon the question of the distinctions between each of these specific pathways; and then seeks to expand on nucleotide excision repair as a possible effector of cellular and clinical resistance to platinum-based anticancer therapy.

Entities:  

Year:  1998        PMID: 19002792      PMCID: PMC3449560          DOI: 10.1023/A:1008016922425

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  77 in total

1.  Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10.

Authors:  M van Duin; J de Wit; H Odijk; A Westerveld; A Yasui; M H Koken; J H Hoeijmakers; D Bootsma
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

2.  Platinum-DNA adduct in head and neck-cancer patients receiving Cisplatin and Carboplatin chemotherapy.

Authors:  R Parker; I Dimery; M Dabholkar; J Vionnet; E Reed
Journal:  Int J Oncol       Date:  1993-08       Impact factor: 5.650

3.  Sequences of taxol and cisplatin: a phase I and pharmacologic study.

Authors:  E K Rowinsky; M R Gilbert; W P McGuire; D A Noe; L B Grochow; A A Forastiere; D S Ettinger; B G Lubejko; B Clark; S E Sartorius
Journal:  J Clin Oncol       Date:  1991-09       Impact factor: 44.544

Review 4.  Appropriate partners make good matches.

Authors:  P Karran
Journal:  Science       Date:  1995-06-30       Impact factor: 47.728

Review 5.  Mechanisms of DNA excision repair.

Authors:  A Sancar
Journal:  Science       Date:  1994-12-23       Impact factor: 47.728

Review 6.  A preliminary risk-benefit assessment of paclitaxel.

Authors:  R J Bitton; W D Figg; E Reed
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

7.  Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.

Authors:  E Reed; S H Yuspa; L A Zwelling; R F Ozols; M C Poirier
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

8.  Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells.

Authors:  J T Drummond; G M Li; M J Longley; P Modrich
Journal:  Science       Date:  1995-06-30       Impact factor: 47.728

Review 9.  P53, cell cycle control and apoptosis: implications for cancer.

Authors:  M B Kastan; C E Canman; C J Leonard
Journal:  Cancer Metastasis Rev       Date:  1995-03       Impact factor: 9.264

10.  GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells.

Authors:  F Palombo; P Gallinari; I Iaccarino; T Lettieri; M Hughes; A D'Arrigo; O Truong; J J Hsuan; J Jiricny
Journal:  Science       Date:  1995-06-30       Impact factor: 47.728

View more
  10 in total

Review 1.  New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA.

Authors:  Jan Reedijk
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-24       Impact factor: 11.205

2.  Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1.

Authors:  Rui Gao; Douglas K Price; Tristan Sissung; Eddie Reed; William D Figg
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

3.  Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells.

Authors:  Guangyu Zhu; MyatNoeZin Myint; Wee Han Ang; Lina Song; Stephen J Lippard
Journal:  Cancer Res       Date:  2011-12-16       Impact factor: 12.701

4.  A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.

Authors:  Yan Zhang; Junli Ma; Sai Zhang; Ganlu Deng; Xiaoling Wu; Jingxuan He; Haiping Pei; Hong Shen; Shan Zeng
Journal:  Int J Colorectal Dis       Date:  2015-06-09       Impact factor: 2.571

5.  Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.

Authors:  William D Figg; Cindy H Chau; Ravi A Madan; James L Gulley; Rui Gao; Tristan M Sissung; Shawn Spencer; Melony Beatson; Jeanny Aragon-Ching; Seth M Steinberg; William L Dahut
Journal:  Clin Genitourin Cancer       Date:  2013-05-17       Impact factor: 2.872

6.  Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?

Authors:  Rui Gao; Kelie M Reece; Tristan Sissung; Samuel H Fu; David J Venzon; Eddie Reed; Shawn D Spencer; Douglas K Price; William D Figg
Journal:  BMJ Open       Date:  2013-01-03       Impact factor: 2.692

7.  Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer.

Authors:  Chang-Sheng Lin; Tu-Chen Liu; Ji-Ching Lai; Shun-Fa Yang; Thomas Chang-Yao Tsao
Journal:  Int J Med Sci       Date:  2017-11-02       Impact factor: 3.738

8.  Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance.

Authors:  Weiwei Wang; Lijun Zhang; Liang Liu; Yongfa Zheng; Yong Zhang; Siyuan Yang; Rongliang Shi; Shaojia Wang
Journal:  Oncol Rep       Date:  2017-02-14       Impact factor: 3.906

9.  β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK.

Authors:  Quentin Q Li; Rebecca X Lee; Huasheng Liang; Gangduo Wang; Jueli M Li; Yuhua Zhong; Eddie Reed
Journal:  Int J Oncol       Date:  2013-06-28       Impact factor: 5.650

10.  Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.

Authors:  Sheng Li; Liangjun Zhu; Li Yao; Lei Xia; Liangxi Pan
Journal:  BMC Gastroenterol       Date:  2014-08-29       Impact factor: 3.067

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.